BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 11544342)

  • 1. Terminal deoxynucleotidyl transferase deficiency decreases autoimmune disease in MRL-Fas(lpr) mice.
    Feeney AJ; Lawson BR; Kono DH; Theofilopoulos AN
    J Immunol; 2001 Sep; 167(6):3486-93. PubMed ID: 11544342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Terminal deoxynucleotidyltransferase deficiency decreases autoimmune disease in diabetes-prone nonobese diabetic mice and lupus-prone MRL-Fas(lpr) mice.
    Robey IF; Peterson M; Horwitz MS; Kono DH; Stratmann T; Theofilopoulos AN; Sarvetnick N; Teyton L; Feeney AJ
    J Immunol; 2004 Apr; 172(7):4624-9. PubMed ID: 15034081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a genetic deficiency of terminal deoxynucleotidyl transferase on autoantibody production by C57BL6 Fas(lpr) mice.
    Molano ID; Wloch MK; Alexander AA; Watanabe H; Gilkeson GS
    Clin Immunol; 2000 Jan; 94(1):24-32. PubMed ID: 10607487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Terminal deoxynucleotidyl transferase deficiency reduces the incidence of autoimmune nephritis in (New Zealand Black x New Zealand White)F1 mice.
    Conde C; Weller S; Gilfillan S; Marcellin L; Martin T; Pasquali JL
    J Immunol; 1998 Dec; 161(12):7023-30. PubMed ID: 9862739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deficient leptin signaling ameliorates systemic lupus erythematosus lesions in MRL/Mp-Fas lpr mice.
    Fujita Y; Fujii T; Mimori T; Sato T; Nakamura T; Iwao H; Nakajima A; Miki M; Sakai T; Kawanami T; Tanaka M; Masaki Y; Fukushima T; Okazaki T; Umehara H
    J Immunol; 2014 Feb; 192(3):979-84. PubMed ID: 24391210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paucity of V-D-D-J rearrangements and VH replacement events in lupus prone and nonautoimmune TdT-/- and TdT+/+ mice.
    Watson LC; Moffatt-Blue CS; McDonald RZ; Kompfner E; Ait-Azzouzene D; Nemazee D; Theofilopoulos AN; Kono DH; Feeney AJ
    J Immunol; 2006 Jul; 177(2):1120-8. PubMed ID: 16818769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FAS(lprcg)/FAS(lprcg) mice.
    Yasuda T; Yoshimoto T; Tsubura A; Matsuzawa A
    Cell Immunol; 2001 Jun; 210(2):77-86. PubMed ID: 11520074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AID dysregulation in lupus-prone MRL/Fas(lpr/lpr) mice increases class switch DNA recombination and promotes interchromosomal c-Myc/IgH loci translocations: modulation by HoxC4.
    White CA; Seth Hawkins J; Pone EJ; Yu ES; Al-Qahtani A; Mai T; Zan H; Casali P
    Autoimmunity; 2011 Dec; 44(8):585-98. PubMed ID: 21585311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of autoimmune disease and of massive lymphadenopathy in MRL/Mp-lpr/lpr mice lacking tyrosine kinase Fyn (p59fyn).
    Takahashi T; Yagi T; Kakinuma S; Kurokawa A; Okada T; Takatsu K; Aizawa S; Katagiri T
    J Immunol; 1997 Sep; 159(5):2532-41. PubMed ID: 9278347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deletion of receptor for advanced glycation end products exacerbates lymphoproliferative syndrome and lupus nephritis in B6-MRL Fas lpr/j mice.
    Goury A; Meghraoui-Kheddar A; Belmokhtar K; Vuiblet V; Ortillon J; Jaisson S; Devy J; Le Naour R; Tabary T; Cohen JH; Schmidt AM; Rieu P; Touré F
    J Immunol; 2015 Apr; 194(8):3612-22. PubMed ID: 25762779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Origin of CD4-CD8-B220+ T cells in MRL-lpr/lpr mice. Clues from a T cell receptor beta transgenic mouse.
    Zhou T; Bluethmann H; Eldridge J; Berry K; Mountz JD
    J Immunol; 1993 Apr; 150(8 Pt 1):3651-67. PubMed ID: 7682246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-12 deficiency in MRL-Fas(lpr) mice delays nephritis and intrarenal IFN-gamma expression, and diminishes systemic pathology.
    Kikawada E; Lenda DM; Kelley VR
    J Immunol; 2003 Apr; 170(7):3915-25. PubMed ID: 12646661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intestinal intraepithelial lymphocyte T cells are resistant to lpr gene-induced T cell abnormalities.
    Aicher WK; Fujihashi K; Taguchi T; McGhee JR; Yamamoto M; Eldridge JH; Gay S; Kiyono H
    Eur J Immunol; 1992 Jan; 22(1):137-45. PubMed ID: 1346108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of genetic deficiency of terminal deoxynucleotidyl transferase on autoantibody production and renal disease in MRL/lpr mice.
    Molano ID; Redmond S; Sekine H; Zhang XK; Reilly C; Hutchison F; Ruiz P; Gilkeson GS
    Clin Immunol; 2003 Jun; 107(3):186-97. PubMed ID: 12804532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Composition and variation analysis of TCR β-chain CDR3 repertoire in the thymus and spleen of MRL/lpr mouse at different ages.
    Li Z; Long M; ChunMei L; Bin S; Jiang Y; Rui M; Qingqing M; XinSheng Y
    Immunogenetics; 2015 Jan; 67(1):25-37. PubMed ID: 25335895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type I IFN protects against murine lupus.
    Hron JD; Peng SL
    J Immunol; 2004 Aug; 173(3):2134-42. PubMed ID: 15265950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Negative role of colony-stimulating factor-1 in macrophage, T cell, and B cell mediated autoimmune disease in MRL-Fas(lpr) mice.
    Lenda DM; Stanley ER; Kelley VR
    J Immunol; 2004 Oct; 173(7):4744-54. PubMed ID: 15383612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of T cell-dependent autoantibody production by a gammadelta T cell line derived from lupus-prone mice.
    Fujii T; Okada M; Craft J
    Cell Immunol; 2002; 217(1-2):23-35. PubMed ID: 12425998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fas/Fas ligand deficiency results in altered localization of anti-double-stranded DNA B cells and dendritic cells.
    Fields ML; Sokol CL; Eaton-Bassiri A; Seo S; Madaio MP; Erikson J
    J Immunol; 2001 Aug; 167(4):2370-8. PubMed ID: 11490027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
    Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A
    J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.